Table 2.
Relationship between UF-DCE parameters and prognostic markers of breast carcinoma
| MS | TTE | BAT | Reference | |
|---|---|---|---|---|
| Invasive or in situ | Invasive ca. > DCIS | Invasive ca. < DCIS | Invasive ca. < DCIS | 18, 24–27 |
| Proliferative marker (Ki-67) status | High > Low | High < Low | 4, 25, 26 | |
| Histological or nuclear grade | High > Low | High < Low | High < Low | 4, 25, 26, 27 |
| ER status | Negative > Positive | Negative < Positive | 4 | |
| HER2 status | Positive > Negative | 26 | ||
| Intrinsic subtype | Triple negative > Non-triple negative | Triple negative < Non-triple negative | Triple negative or HER2 type < Luminal type | 27, 28 |
| Axillary lymph node metastasis | Positive > Negative | 25 |
BAT, bolus arrival time; ER, estrogen receptor; HER2, human epidermal growth factor receptor 2; MS, maximum slope; TTE, time to enhancement.